Orlic D, Smerdelj M, Kolundzic R, Bergovec M
Department of Orthopaedic Surgery, Clinical Hospital Centre Zagreb and Zagreb University School of Medicine, Zagreb, Croatia.
Int Orthop. 2006 Dec;30(6):458-64. doi: 10.1007/s00264-006-0193-9. Epub 2006 Aug 8.
We retrospectively analysed 90 patients who underwent "en bloc" resection and modular endoprosthesis reconstruction in the lower limbs between 1987-2003. After proximal femur resection, reconstruction was performed with a modular endoprosthesis by Howmedica (KFTR, designed by Kotz) and modular revision endoprosthesis by W. Link or Lima-Lto (Revision system, designed by Wagner). The knee joint was reconstructed with a modular endoprosthesis (Howmedica, KFTR designed by Kotz) after distal femur or proximal tibia resection. Malignant bone tumours were present in 58 patients (64.5%), benign tumours in 16 (17.8%), metastases in 8 (8.9%), tumour-like lesions in 4 (4.4 %) and non-tumour-related destruction of the femur in 4 patients (4.4%). High-grade tumours were found in the majority of malignant bone tumours (70.7%). Treatment complications, which occurred in 26 patients, were: local recurrence of the tumour, deep infection, acetabular destruction following hemiarthroplasty, recurrent dislocations of endoprosthesis, periprosthetic fracture and hardware problems. In total, 23 patients (25.6%) died due to tumours. Endoprostheses should be considered as a treatment of choice for bone tumours in the hip and knee joint region. Advances in limb salvage surgery are, and will long continue to be, a great challenge for orthopaedic oncologists of the 21st century.
我们回顾性分析了1987年至2003年间90例行下肢“整块”切除及模块化假体重建术的患者。股骨近端切除术后,采用Howmedica公司的模块化假体(KFTR,由Kotz设计)以及W. Link或Lima-Lto公司的模块化翻修假体(翻修系统,由Wagner设计)进行重建。股骨远端或胫骨近端切除术后,采用模块化假体(Howmedica,KFTR由Kotz设计)重建膝关节。58例患者(64.5%)存在恶性骨肿瘤,16例(17.8%)为良性肿瘤,8例(8.9%)为转移瘤,4例(4.4%)为肿瘤样病变,4例(4.4%)为与肿瘤无关的股骨破坏。大多数恶性骨肿瘤(70.7%)为高级别肿瘤。26例患者出现治疗并发症,包括:肿瘤局部复发、深部感染、半关节置换术后髋臼破坏、假体反复脱位、假体周围骨折及内固定问题。共有23例患者(25.6%)死于肿瘤。对于髋膝关节区域的骨肿瘤,应将假体视为一种治疗选择。肢体挽救手术的进展过去是、今后很长一段时间仍将是21世纪骨肿瘤外科医生面临的巨大挑战。